Studies present a wider application of sequencing techniques for the treatment of cancer
Whole-genome sequencing and single-cell sequencing can provide valuable insights not only in the identification of new therapy targets, but also to assess minimal residual disease and overcome treatment resistance
Liquid biopsies are quickly evolving beyond ctDNA, but technical challenges remain
Newly-presented studies highlight that insights into cancer can also be unlocked from circulating tumour cells, exosomal microRNA and cell-free RNA
Data from molecular analyses unveil diverse resistance mechanisms to endocrine therapy in breast cancer
Among the presented findings, a potential role for ESR1 gene fusions was observed
Adjuvant immunotherapy continues to confirm its efficacy in melanoma
Updated data from two studies report significant improvements in recurrence-free survival and distant-metastasis free survival with pembrolizumab or nivolumab
A c-Met directed antibody-drug conjugate shows preliminary activity in a NSCLC cohort
Efficacy and safety of telisotuzumab adizutecan was investigated in patients with EGFR wild type non-squamous disease
Frontline abemaciclib plus endocrine therapy showed superior efficacy compared to chemotherapy in aggressive HR+/HER2– breast cancer
The combination therapy with the CDK 4/6 inhibitor improved overall response rate compared to standard treatment
Promising antitumour activity presented for emerging targets in different solid tumours
Strategies to target MTAP deletion, KRAS G12D and ESR1 mutations, and CDK4 and CDK2 further expand the landscape of precision oncology
Drug Rediscovery Protocol-like Clinical Trials facilitate access to precision oncology
Data from studies presented highlight the importance of integrating and incorporating comprehensive genomic profiling into clinical practice across a broad range of tumour types
Some clinical activity was reported for novel tyrosine kinase inhibitors in previously treated patients with GIST
However, the future of TKI combinations for these rare tumours is uncertain
Alectinib shows benefit across genetic profiles in resected ALK-positive NSCLC
New data from the ALINA study confirm lack of influence of EML4-ALK variant on outcome in this patient population